Pfizer to acquire Seagen for $43 billion
To advance cancer breakthroughs, antibody-drug conjugates (ADCs) are the central technology in Pfizer’s intended acquisition of Seagen Inc.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
